Navigation Links
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
Date:10/2/2008

Ph.D., Orexigen President and CEO. "Based on our preclinical data, we believe that OREX-003 has the potential to have an improved metabolic profile and be a more effective long-term option in the management of schizophrenia and a number of related conditions."

About OZ-101

The OZ-101 clinical trial is a double-blind, placebo-controlled clinical trial evaluating the combination of olanzapine plus zonisamide SR versus olanzapine plus placebo in 75 patients with schizophrenia over 16 weeks at nine centers in the U.S. Preclinical studies conducted by Orexigen have demonstrated that zonisamide mitigated both weight gain and elevated blood glucose associated with olanzapine through novel mechanisms. The clinical trial is currently enrolling. More information can be found at http://www.clinicaltrials.gov.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in late-stage of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 Strategic marketing and branding agency, ... name, Able&Co. , The agency was founded in 2008 ... its inception, continuing to expand its business each year. ... with a core focus on branding and marketing strategy. ... name and visual identity to reflect who we have ...
(Date:3/6/2015)... Global Specimen Solutions, Inc. ( http://www.globalspecimensolutions.com ... management and informatics, announced today that Series A ... is excited to catapult our growing momentum in ... enhance our proprietary informatics tools and infrastructure to ... has proved rapid market uptake of our clinical ...
(Date:3/6/2015)... , March 6, 2015   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... Company,s fourth quarter and full year 2014 financial results will ... the Company will host a conference call and live ...
(Date:3/5/2015)... New York (PRWEB) March 05, 2015 ... veterans to be able to get an Advanced Semen ... money, stress, blaming and guessing are all risk factors ... assuming the woman is the source of the infertility. ... female. LifeCell Dx has the simplest, least complicated ...
Breaking Biology Technology:Red House Group Reveals New Identity as Able&Co. 2Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3
... MYL ) today announced that it has received ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... the generic version of Merck and Co.,s Singulair(R), which ... the 12 months ending March 31 for the same ...
... announced that it will present preliminary data from its Phase I ... the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.Dr ... be presenting the poster in the Develop m ... Vascula r ...
... May 28 The 500th patient was supported with ... as the,"Berlin Heart") since the first implantation of the ... device at the Children,s Memorial,Hospital in Chicago and has ... Alejandra had been diagnosed a few weeks ...
Cached Biology Technology:Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO 2500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device 2
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... the University of Sheffield and Queen Mary, University of ... damage by sunlight when they are faced with extreme ... Nature, could have implications both for adapting plants to ... better harness solar energy. Photosynthesis in plants ...
... fickle as wind itself, can be groomed to become ... a lower cost than at present, according to scientists ... wind farms throughout a given geographic area with transmission ... into one powerful energy source. The findings are ...
... studied and controversial ecogeographical patterns, and refers to the ... Although it has been studied since the mid 19th ... techniques have made it possible to disentangle the underlying ... study in the journal Ecography, an international team of ...
Cached Biology News:Scientists unravel plants' natural defenses 2The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source 2The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source 3The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source 4
... (Vesicle-Associated Membrane Protein 2, Synaptobrevin ... share homology with any other ... is expected that the antibody ... Macaca multata and bovine due ...
MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
Biology Products: